BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed signs of anti-tumor activity, including an unconfirmed partial response, stable disease ≥ 12 weeks in 3/3 non-small cell lung cancer patients and in 2/3 patients at the highest dose Bolt is running a partnering process to advance development of BDC-3042 ...

Core Insights - Bolt Biotherapeutics is set to present data from its Phase 1 dose-escalation clinical study of BDC-3042 at the AACR Annual Meeting in April 2025, focusing on patients with advanced cancers [1][2] Group 1: Clinical Study Details - BDC-3042 is a proprietary agonist antibody targeting dectin-2, an immune-activating receptor found in tumor-associated macrophages, and is being evaluated in patients with metastatic or unresectable solid tumors, including non-small cell lung cancer (NSCLC) [2][7] - The Phase 1 clinical study is a single-agent, dose-escalation trial assessing the safety and efficacy of BDC-3042 [2][7] Group 2: Presentation Information - The poster presentation titled "BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study" will be presented by Dr. Ecaterina E. Dumbrava on April 29, 2025 [4] - Additional presentations will include preclinical data on Boltbody™ ISACs targeting CEA and PD-L1, showcasing the company's innovative approaches to cancer treatment [2][4] Group 3: Boltbody™ ISAC Platform - The Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform combines tumor-targeting antibodies with immune stimulants to enhance anti-cancer responses by activating myeloid cells [5] - This platform aims to create a robust immune response within the tumor microenvironment, potentially leading to durable therapeutic outcomes for cancer patients [5] Group 4: Company Overview - Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment, leveraging expertise in myeloid biology and cancer drug development [6][7] - The company's pipeline includes BDC-3042 and BDC-4182, with the latter expected to enter clinical trials in the second quarter of 2025 [7]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Biotherapeutics, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 47-2804636 | | ...

Exhibit 99.1 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update REDWOOD CITY, CA, Mar. 24, 2025 – Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended December 31, 2024, and provided a business update. "2024 was a transformational year for Bolt as we focused the company on efficient development of the ...

BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be reported in second quarter 2025Cash balance of $70.2 million as of December 31, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunother ...

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 45th Annual Health Care ConferenceCompany presentation on Tuesday, March 4, 2025 at 3:10 p.m. EST (1:10 p.m. PST) Leerink Partners Global Healthcare ConferenceParticipating in 1x1 meetings on Monday, March 10, 2025 Abo ...

-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The collaborators are developing a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple solid tumor types. Under the existing Joint Development and License A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Biotherapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-2804636 (State or other ...

Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update • Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC3042 in patients with advanced cancers • Presented updated preclinical activity of BDC-4182 and key learnings from Phase 1 doseescalation trial of BDC-1001 at the SITC 39th Annual Meeting • BDC-4182 on track to start clinical trials in second quarter 2025 • Cash balance of $84.4 million as of September 30, 2024 an ...

Toronto, Ontario--(Newsfile Corp. - Le 11 novembre/November 2024) - Bolt Metals Corp. has announced a two (2) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive one (1) additional share for each share held on such date. Upon completion of the split, there will be approximately 31,381,412 shares issued and outstanding. Please note that all open orders will be canceled at the close of business on Nove ...